SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
Meets primary endpoints- SCI-110 administration was found to be safe at all tested doses SCI-110…
Month: November 2022
RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit
Glen Rock, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or…
Yield10 Bioscience to Announce Third Quarter 2022 Financial Results and Host a Conference Call on Monday, November 14, 2022
WOBURN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the…
Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022
LAWRENCEVILLE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) — Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug-development…
Intelligent Bio Solutions Inc. (INBS) Announces UK-Wide Glass Manufacturer to Roll Out Non-Invasive Drug Screening System Across UK Operations
– Can now test 1,000 employees across six sites as required, with each test always…
HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics Prize
LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in…
Dyadic to Present at Upcoming Industry and Investor Events in November
JUPITER, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
CorMedix Inc. Announces CMS Revision to NTAP Reimbursement of DefenCath
BERKELEY HEIGHTS, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types
Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modification…
SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi
Ibrexafungerp demonstrates activity against deadly fungal pathogens included in the World Health Organization’s (WHO) first…
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
FREMONT, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ:…
Aphaia Pharma to Participate in the LSX Leaders Inv€$tival Showcase
ZUG, Switzerland, Nov. 07, 2022 (GLOBE NEWSWIRE) — Aphaia Pharma, a clinical-stage company harnessing precision-targeted…
Biora Therapeutics Announces $9.75 Million Direct Offering
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage…
Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients
• Signs of intra-tumor pro-inflammatory state in patients• Temferon™ induced immune system reset in preclinical…
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting
BELTSVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company…
Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Initial clinical data of AHR antagonist, IK-175, shows treatment is well-tolerated and demonstrates anti-tumor activity…
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like…
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK…
Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a…